Litigation Details for Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. (D. Del. 2018)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-07-16 |
| Court | District Court, D. Delaware | Date Terminated | 2022-10-20 |
| Cause | 35:271 Patent Infringement | Assigned To | Kent A. Jordan |
| Jury Demand | Defendant | Referred To | |
| Patents | 8,324,283; 9,187,405 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-07-16 | 1 | Complaint | mg, prior to expiration of U.S. Patent No. 9,187,405 (“the ’405 patent”). …1. This is an action for patent infringement arising under the patent laws of the United States, …)(IV), with respect to the ’405 patent asserting that the ’405 patent is invalid, unenforceable, and/…)(IV), with respect to the ’405 patent asserting that the ’405 patent is invalid, unenforceable, and/…)(IV), with respect to the ’405 patent asserting that the ’405 patent is invalid, unenforceable, and/ | External link to document |
| 2018-11-05 | 237 | Stipulation | alleging infringement of U.S. Patent No. 9,187,405 (“the ’405 patent”) based on Apotex’s submission …of the ’405 patent before the Patent Trials and Appeals Board; WHEREAS, the Patent Trial and Appeal…regarding the validity, patentability, or unenforceability of the ’405 patent. Upon entry of the last…regarding the validity, patentability, or unenforceability of the ’405 patent. Any judgment or determination…regarding the validity, patentability, or unenforceability of the ’405 patent, then either Party may | External link to document |
| 2018-12-12 | 293 | Notice of Service | Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by HEC Pharm Co., Ltd., HEC Pharm … 16 July 2018 1:18-cv-01043 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-02-13 | 354 | Notice of Service | Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing… 16 July 2018 1:18-cv-01043 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-02-20 | 392 | Notice of Service | of Invalidity References Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing… 16 July 2018 1:18-cv-01043 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2018-07-16 | 4 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,187,405. (nmg) (Entered: 07… 16 July 2018 1:18-cv-01043 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
